These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 38252441)
1. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort. Iams WT; Mackay M; Ben-Shachar R; Drews J; Manghnani K; Hockenberry AJ; Cristofanilli M; Nimeiri H; Guinney J; Benson AB JAMA Netw Open; 2024 Jan; 7(1):e2351700. PubMed ID: 38252441 [TBL] [Abstract][Full Text] [Related]
2. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761 [TBL] [Abstract][Full Text] [Related]
3. Targeted mutation detection in breast cancer using MammaSeq™. Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836 [TBL] [Abstract][Full Text] [Related]
4. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan. Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582 [TBL] [Abstract][Full Text] [Related]
6. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. Mack PC; Banks KC; Espenschied CR; Burich RA; Zill OA; Lee CE; Riess JW; Mortimer SA; Talasaz A; Lanman RB; Gandara DR Cancer; 2020 Jul; 126(14):3219-3228. PubMed ID: 32365229 [TBL] [Abstract][Full Text] [Related]
7. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887 [TBL] [Abstract][Full Text] [Related]
8. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340 [TBL] [Abstract][Full Text] [Related]
9. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595 [TBL] [Abstract][Full Text] [Related]
10. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984 [TBL] [Abstract][Full Text] [Related]
11. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing. Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823 [TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. Aggarwal C; Thompson JC; Black TA; Katz SI; Fan R; Yee SS; Chien AL; Evans TL; Bauml JM; Alley EW; Ciunci CA; Berman AT; Cohen RB; Lieberman DB; Majmundar KS; Savitch SL; Morrissette JJD; Hwang WT; Elenitoba-Johnson KSJ; Langer CJ; Carpenter EL JAMA Oncol; 2019 Feb; 5(2):173-180. PubMed ID: 30325992 [TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968 [TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. Tran HT; Lam VK; Elamin YY; Hong L; Colen R; Elshafeey NA; Hassan ISA; Altan M; Blumenschein GR; Rinsurongkawong W; Rivera MJ; Vasquez ME; Carter BW; Byers LE; Tsao AS; Gibbons DL; Fossella F; Glisson BS; Zhang J; Heymach JV JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34377884 [TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer. Lin Z; Li Y; Tang S; Deng Q; Jiang J; Zhou C Lung Cancer; 2023 Aug; 182():107282. PubMed ID: 37392713 [TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy. Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552 [TBL] [Abstract][Full Text] [Related]
18. Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial. García-Pardo M; Czarnecka-Kujawa K; Law JH; Salvarrey AM; Fernandes R; Fan ZJ; Waddell TK; Yasufuku K; Liu G; Donahoe LL; Pierre A; Le LW; Gunasegaran T; Ghumman N; Shepherd FA; Bradbury PA; Sacher AG; Schmid S; Corke L; Feng J; Stockley T; Pal P; Rogalla P; Pipinikas C; Howarth K; Ambasager B; Mezquita L; Tsao MS; Leighl NB JAMA Netw Open; 2023 Jul; 6(7):e2325332. PubMed ID: 37490292 [TBL] [Abstract][Full Text] [Related]
19. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187 [TBL] [Abstract][Full Text] [Related]
20. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients. Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]